The Protein Kinase 2 Inhibitor CX-4945 Induces Autophagy in Human Cancer Cell Lines

被引:1
|
作者
Kim, Jiyeon [2 ]
Park, Mikyung [1 ,3 ]
Ryu, Byung Jun [1 ]
Kim, Seong Hwan [1 ]
机构
[1] Korea Res Inst Chem Technol, Pharmacol Res Ctr, Lab Translat Therapeut, Taejon 305600, South Korea
[2] Eulji Univ, Sch Med, Dept Biomed Lab Sci, Taejon 301746, South Korea
[3] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea
基金
新加坡国家研究基金会;
关键词
CK2; CK-4945; Autophagy; Cancer; CK2; DEATH; TARGET; MTOR;
D O I
10.5012/bkcs.2014.35.10.2985
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Autophagy is a self-digestion process in which intracellular structures are degraded in response to stress. Notably, prolonged autophagy leads to cell death. In this study, we investigated whether CX-4945, an orally available protein kinase 2 (CK2) inhibitor, induces autophagic cell death in human cervical cancer-derived HeLa cells and in human prostate cancer-derived LNCaP cells. CX-4945 treatment of both cell lines resulted in the formation of autophagosomes, in the conversion of microtubule-associated protein 1 light chain 3 (LC3), and in down-regulation of the Akt-mammalian target of rapamycin (mTOR)-p70 ribosomal protein S6 kinase (S6K) signaling cascade. Thus, pharmacologic inhibition of CK2 by CX-4945 induced autophagic cell death in human cancer cells by down-regulating Akt-mTOR-S6K. These results suggest that autophagy-inducing agents have potential as anti-cancer drugs.
引用
收藏
页码:2985 / 2989
页数:5
相关论文
共 50 条
  • [1] Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines
    Hwang, Dae Wook
    So, Kwang Sup
    Kim, Song Cheol
    Park, Kwang-Min
    Lee, Young-Joo
    Kim, Sun-Whe
    Choi, Chang-Min
    Rho, Jin Kyung
    Choi, Yun Jung
    Lee, Jae Cheol
    PANCREAS, 2017, 46 (04) : 575 - 581
  • [2] Structural basis of CX-4945 binding to human protein kinase CK2
    Ferguson, Andrew D.
    Sheth, Payal R.
    Basso, Andrea D.
    Paliwal, Sunil
    Gray, Kimberly
    Fischmann, Thierry O.
    Le, Hung V.
    FEBS LETTERS, 2011, 585 (01) : 104 - 110
  • [3] The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1
    Lee, Da Sol
    Lee, Seonmin
    Kim, Chorong
    Kim, Danbee
    Kim, Kyu-Pyo
    Yoo, Changhoon
    ANTICANCER RESEARCH, 2022, 42 (07) : 3435 - 3443
  • [4] CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
    Masyk, Maciej
    Janeczko, Monika
    Martyna, Aleksandra
    Kubinski, Konrad
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2017, 435 (1-2) : 193 - 196
  • [5] Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance
    D'Amore, Claudio
    Borgo, Christian
    Sarno, Stefania
    Salvi, Mauro
    CELLULAR ONCOLOGY, 2020, 43 (06) : 1003 - 1016
  • [6] Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
    Girardi, Cristina
    Ottaviani, Daniele
    Pinna, Lorenzo A.
    Ruzzene, Maria
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [7] Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
    Claudio D’Amore
    Christian Borgo
    Stefania Sarno
    Mauro Salvi
    Cellular Oncology, 2020, 43 : 1003 - 1016
  • [8] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Fabrice Pierre
    Peter C. Chua
    Sean E. O’Brien
    Adam Siddiqui-Jain
    Pauline Bourbon
    Mustapha Haddach
    Jerome Michaux
    Johnny Nagasawa
    Michael K. Schwaebe
    Eric Stefan
    Anne Vialettes
    Jeffrey P. Whitten
    Ta Kung Chen
    Levan Darjania
    Ryan Stansfield
    Joshua Bliesath
    Denis Drygin
    Caroline Ho
    May Omori
    Chris Proffitt
    Nicole Streiner
    William G. Rice
    David M. Ryckman
    Kenna Anderes
    Molecular and Cellular Biochemistry, 2011, 356 : 37 - 43
  • [9] Validation of an LC-MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
    Schwarz, Rico
    Richter, Anna
    Ito, Elisabeth R. D.
    Escobar, Hugo Murua
    Junghanss, Christian
    Hinz, Burkhard
    MOLECULES, 2022, 27 (08):
  • [10] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Pierre, Fabrice
    Chua, Peter C.
    O'Brien, Sean E.
    Siddiqui-Jain, Adam
    Bourbon, Pauline
    Haddach, Mustapha
    Michaux, Jerome
    Nagasawa, Johnny
    Schwaebe, Michael K.
    Stefan, Eric
    Vialettes, Anne
    Whitten, Jeffrey P.
    Chen, Ta Kung
    Darjania, Levan
    Stansfield, Ryan
    Bliesath, Joshua
    Drygin, Denis
    Ho, Caroline
    Omori, May
    Proffitt, Chris
    Streiner, Nicole
    Rice, William G.
    Ryckman, David M.
    Anderes, Kenna
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 356 (1-2) : 37 - 43